Literature DB >> 29697788

What Are the Targets of Inflammatory Bowel Disease Management.

Sara Lega1,2, Marla C Dubinsky3.   

Abstract

With recent evidence suggesting that keeping the inflammatory process under tight control prevents long-term disability, the aim of treatments in inflammatory bowel disease (IBD) has shifted from symptom control toward the resolution of bowel inflammation. Mucosal healing is currently recognized as the principal treatment target to be used in a "treat to target" paradigm, whereas histologic healing and normalization of biomarkers are being evaluated as potential future targets. Although symptom relief is no longer a sufficient target, patient experience with the disease is of unquestionable importance and should be assessed in the form of patient-reported outcomes, to be used as a co-primary target with an objective measure of disease activity. IBD in is a heterogeneous disease; thus besides defining common treatment targets, every effort should be made to deliver a personalized treatment plan based on the risk factors for disease progression and individual drug metabolism to improve treatment success.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29697788     DOI: 10.1093/ibd/izy064

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

1.  Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm.

Authors:  Suruchi Batra; Laurie S Conklin
Journal:  Handb Exp Pharmacol       Date:  2020

Review 2.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

3.  Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores?

Authors:  Dimitrios S Politis; Konstantinos H Katsanos; Konstantinos Papamichael; Maria Saridi; Eleni Albani; Dimitrios K Christodoulou
Journal:  World J Gastrointest Endosc       Date:  2019-06-16

4.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

Authors:  David M Faleck; Adam Winters; Shreya Chablaney; Preeti Shashi; Joseph Meserve; Aaron Weiss; Satimai Aniwan; Jenna L Koliani-Pace; Gursimran Kochhar; Brigid S Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Varun Kesar; Karen Lasch; Michelle Luo; Matthew Bohm; Sashidhar Varma; Monika Fischer; David Hudesman; Shannon Chang; Dana Lukin; Keith Sultan; Arun Swaminath; Nitin Gupta; Corey A Siegel; Bo Shen; William J Sandborn; Sunanda Kane; Edward V Loftus; Bruce E Sands; Jean-Frederic Colombel; Parambir S Dulai; Ryan Ungaro
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-06       Impact factor: 11.382

Review 5.  NF-κB signaling in inflammation and cancer.

Authors:  Tao Zhang; Chao Ma; Zhiqiang Zhang; Huiyuan Zhang; Hongbo Hu
Journal:  MedComm (2020)       Date:  2021-12-16

Review 6.  Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?

Authors:  Panu Wetwittayakhlang; Livia Lontai; Lorant Gonczi; Petra A Golovics; Gustavo Drügg Hahn; Talat Bessissow; Peter L Lakatos
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

7.  Perspectives of primary care providers and endoscopists about current practices, facilitators and barriers for preparation and follow-up of colonoscopy procedures: a qualitative study.

Authors:  Gayle Restall; John R Walker; Celeste Waldman; Kathleen Zawaly; Valerie Michaud; Dana Moffat; Harminder Singh
Journal:  BMC Health Serv Res       Date:  2018-10-17       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.